Comparative Pharmacology
Head-to-head clinical analysis: GABAPENTIN ENACARBIL versus VIGPODER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABAPENTIN ENACARBIL versus VIGPODER.
GABAPENTIN ENACARBIL vs VIGPODER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin enacarbil is a prodrug of gabapentin. It binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. This modulates neuronal excitability and pain transmission.
VIGPODER (vigabatrin) is an irreversible inhibitor of GABA transaminase, leading to increased brain levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
Initial: 600 mg orally once daily; titrate to 600 mg three times daily; max 2400 mg/day divided three times daily.
150 mg orally twice daily with or without food.
None Documented
None Documented
Clinical Note
moderateGabapentin enacarbil + Venlafaxine
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Venlafaxine."
Clinical Note
moderateGabapentin enacarbil + Nefazodone
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Nefazodone."
Clinical Note
moderateGabapentin enacarbil + Stiripentol
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Stiripentol."
Clinical Note
moderateTerminal half-life of gabapentin: 5–7 hours in patients with normal renal function. Renal impairment prolongs half-life proportionally to creatinine clearance decline.
12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl 30–50 mL/min).
Renal: 100% as unchanged gabapentin (prodrug is rapidly hydrolyzed to gabapentin after absorption). No biliary or fecal elimination of active drug.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% via other routes.
Category A/B
Category C
Anticonvulsant
Anticonvulsant
Gabapentin enacarbil + Pomalidomide
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Pomalidomide."